← Back to all signals
RESEARCH PAPER ANALYSIS

Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease.

In a 6-OHDA rat model of Parkinson's disease, oral rutin (10 mg/kg for 14 days) reduced intestinal inflammation—decreasing intraepithelial lymphocytes, goblet cell changes, and ileal Paneth cell hyperplasia—while selected gut bacterial taxa measured by PCR were unchanged.

PMID41903068
JournalNeurotoxicity research
Publication Date2026-03-28
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

In a 6-OHDA rat model of Parkinson's disease, oral rutin (10 mg/kg for 14 days) reduced intestinal inflammation—decreasing intraepithelial lymphocytes, goblet cell changes, and ileal Paneth cell hyperplasia—while selected gut bacterial taxa measured by PCR were unchanged.

WHY IT MATTERS

Research significance

This supports the idea that a dietary flavonoid can attenuate PD-related enteric inflammation and thus could be a candidate for gut-targeted adjunctive therapies influencing the gut-brain axis, though the study lacks central neuroprotection, behavioral outcomes, mechanistic depth, and comprehensive…

ABSTRACT

Source abstract

The enteric nervous system (ENS), a complex network of neurons and glial cells, is essential for maintaining intestinal homeostasis and is implicated in neurodegenerative diseases such as Parkinson's disease (PD). The gut-brain axis, modulated by gut microbiota (GM), is influenced by dietary compounds that can alter its composition. Despite advances in the understanding of PD pathophysiology, effective treatments remain limited, underscoring the need for novel therapeutic approaches. Among plant-derived compounds, the flavonoid rutin has shown significant antioxidant, anti-inflammatory, and neuroprotective properties in vivo. This study evaluated the effects of rutin on leukocyte infiltration, intestinal morphology, and GM composition in an experimental model of PD. Adult male Wistar rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) and were treated orally with rutin (10 mg/kg) for 14 days. Intestinal segments were analyzed histomorphometrically, and fecal samples were assessed for the abundance of Firmicutes, Bacteroidetes, Prevotellacea, Entererobactereacea, Bifidobacterium sp and Lactobacillus sp. by PCR. Rutin administration significantly reduced intraepithelial lymphocyte infiltration and goblet cell numbers in the ileum and colon and prevented hyperplasia of Paneth cells in the ileum. Importantly, GM composition remained unchanged following rutin treatment. These findings demonstrated that rutin reduces intestinal inflammation in PD models without altering gut microbiota composition, highlighting its potential as a therapeutic strategy.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 15 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 16 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 17 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 18 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 19 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 20 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 21 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 22 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 23 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 24 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 25 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 26 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 27 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 28 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 29 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 30 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 31 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0 32 Vitamins as Modulators of Neurodegenerative Disease Pathways: Mechanisms and Therapeutic Perspectives. Nutrients 74.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic